Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth Weight Infants

Autor: Samira Samiee-Zafarghandy, Christoph P. Hornik, J N van den Anker, Reese H. Clark, M M Laughon, P B Smith
Přispěvatelé: Pediatric Surgery
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Male
medicine.medical_specialty
Pediatrics
Sildenafil
Hypertension
Pulmonary
Vasodilator Agents
Statistics as Topic
Gestational Age
Diagnostic Techniques
Ophthalmological
Risk Assessment
Article
Sildenafil Citrate
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
030225 pediatrics
Intensive care
medicine
Medical Records
Problem-Oriented
Humans
Infant
Very Low Birth Weight
Retinopathy of Prematurity
Neonatology
10. No inequality
Bronchopulmonary Dysplasia
business.industry
Obstetrics and Gynecology
Gestational age
Infant
Retinopathy of prematurity
Odds ratio
medicine.disease
United States
3. Good health
respiratory tract diseases
Low birth weight
chemistry
Pediatrics
Perinatology and Child Health
Cohort
030221 ophthalmology & optometry
cardiovascular system
Female
medicine.symptom
business
Infant
Premature
Zdroj: Journal of perinatology : official journal of the California Perinatal Association
Journal of Perinatology, 36(2), 137-140. Nature Publishing Group
ISSN: 1476-5543
0743-8346
Popis: Objective To examine the effect of sildenafil therapy on development of severe retinopathy of prematurity (ROP) requiring surgical intervention in premature infants. Study Design We identified premature infants who were discharged from Pediatrix Medical Group neonatal intensive care units from 2003–2012 and who received an ophthalmologic exam. We matched each infant exposed to sildenafil prior to first eye exam to three non-exposed infants using propensity scoring to control for differences in baseline infant characteristics. We evaluated the association between sildenafil exposure and development of severe ROP using conditional logistic regression. Result Of the 57815 infants meeting inclusion criteria, 88 were exposed to sildenafil. We matched 81/88 (92%) sildenafil-exposed with 243 non-exposed infants. There was no difference in the proportion of infants who developed severe ROP in the sildenafil-exposed vs. non-exposed groups (17/81 [21%] vs. 38/243 [16%], P=0.27). On adjusted analysis, there was no difference in severe ROP in the sildenafil-exposed versus non-exposed infants (odds ratio=1.46, 95% confidence interval=0.76–2.82, P=0.26). Conclusion We did not observe an association between risk of severe ROP and sildenafil exposure prior to first eye exam in this cohort of premature infants.
Databáze: OpenAIRE
Externí odkaz: